EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immunotherapy for Melanoma: A Concise Clinical Review for Australasian Practice

Alexandra Stacy, Luca Wynn, Nicole Seebacher iD

Australasian Journal of Dermatology · 2026-11 · 67 (7) · 387-393

DOI: 10.1111/ajd.70158 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Australasian Journal of Dermatology, online erschienen am 25.06.2026. Verfasst von Alexandra Stacy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Hospital, Sydney, Australia. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has transformed the management of melanoma and is now a central component of care for patients with high‐risk, unresectable, and metastatic disease. Immune checkpoint inhibitors targeting programmed death 1 (PD‐1), cytotoxic T‐lymphocyte–associated antigen 4 (CTLA‐4), and lymphocyte activation gene 3 (LAG‐3) enhance antitumour immune responses and have resulted in substantial improvements in survival, with durable disease control in a proportion of patients. In Australia and New Zealand, immunotherapy is routinely used across the melanoma disease continuum, including neoadjuvant, adjuvant, and metastatic settings, supported by evolving regulatory approvals and funding pathways. This review summarises current immunotherapy approaches to melanoma, with a focus on how these therapies are used in routine Australian practice, including mechanisms of action, indications across disease stages, commonly used agents, special melanoma subtypes, benefits and limitations of treatment, immune‐related adverse events, particularly cutaneous toxicities, and emerging therapies. The role of dermatologists within multidisciplinary melanoma care is highlighted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsImmunotherapyImmune Checkpoint InhibitorsAntineoplastic Agents, ImmunologicalHumansAustraliaCTLA-4 AntigenProgrammed Cell Death 1 ReceptorLymphocyte Activation Gene 3 Protein

Substanzen

Immune Checkpoint InhibitorsCTLA-4 AntigenProgrammed Cell Death 1 ReceptorAntineoplastic Agents, ImmunologicalLymphocyte Activation Gene 3 Protein

Autor:innen und Institutionen

  • Liverpool Hospital, Sydney, Australia.
  • Orange Health Service, Orange, New South Wales, Australia.
  • The Skin Hospital, Darlinghurst, Sydney, Australia.

ORCID-Profile: Nicole Seebacher

Zitieren

APA

Stacy, A., Wynn, L., & Seebacher, N. (2026). Immunotherapy for Melanoma: A Concise Clinical Review for Australasian Practice. Australasian Journal of Dermatology, 67(7), 387-393. https://doi.org/10.1111/ajd.70158

Vancouver

Stacy A, Wynn L, Seebacher N. Immunotherapy for Melanoma: A Concise Clinical Review for Australasian Practice. Australasian Journal of Dermatology. 2026;67(7):387-393. doi:10.1111/ajd.70158

BibTeX
@article{Stacy2026,
  author = {Stacy, Alexandra and Wynn, Luca and Seebacher, Nicole},
  title = {Immunotherapy for Melanoma: A Concise Clinical Review for Australasian Practice},
  journal = {Australasian Journal of Dermatology},
  year = {2026},
  volume = {67},
  number = {7},
  pages = {387--393},
  doi = {10.1111/ajd.70158}
}
Kostenlos starten →